Loading...
CRBU logo

Caribou Biosciences, Inc.NasdaqGS:CRBU Aktienübersicht

Marktkapitalisierung US$158.2m
Aktienkurs
US$1.60
US$12
86.7% unterbewertet intrinsischer Abschlag
1Y43.7%
7D-16.9%
1D
Wert des Portfolios
​
Siehe

Caribou Biosciences, Inc.

NasdaqGS:CRBU Lagerbericht

Marktkapitalisierung: US$158.2m

Caribou Biosciences (CRBU) Aktienübersicht

Caribou Biosciences, Inc. ist ein in der klinischen Phase befindliches biopharmazeutisches Unternehmen, das Genom-Editing mittels CRISPR (clustered regularly interspaced short palindromic repeats) betreibt. Mehr Details

CRBU grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung0/6
Künftiges Wachstum2/6
Vergangene Leistung0/6
Finanzielle Gesundheit6/6
Dividenden0/6

Belohnungen

Prognostiziertes jährliches Umsatzwachstum 44.39%

Risikoanalyse

Die Erträge werden in den nächsten 3 Jahren voraussichtlich um durchschnittlich 21.3% pro Jahr sinken.

Derzeit unrentabel und in den nächsten 3 Jahren nicht rentabel zu werden prognostiziert


CRBU Community Fair Values

Create Narrative

See what 27 others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Caribou Biosciences, Inc. Wettbewerber

Preisentwicklung & Leistung

Zusammenfassung der Höchst- und Tiefststände sowie der Veränderungen der Aktienkurse für Caribou Biosciences
Historische Aktienkurse
Aktueller AktienkursUS$1.60
52-Wochen-HochUS$3.54
52-Wochen-TiefUS$1.04
Beta2.33
1 Monat Veränderung-25.47%
3 Monate Veränderung-14.71%
1 Jahr Veränderung43.69%
3 Jahre Veränderung-63.25%
5 Jahre Veränderungn/a
Veränderung seit IPO-90.23%

Aktuelle Nachrichten und Updates

Analyseartikel • May 13

Need To Know: Analysts Are Much More Bullish On Caribou Biosciences, Inc. (NASDAQ:CRBU) Revenues

Caribou Biosciences, Inc. ( NASDAQ:CRBU ) shareholders will have a reason to smile today, with the analysts making...

Recent updates

Analyseartikel • May 13

Need To Know: Analysts Are Much More Bullish On Caribou Biosciences, Inc. (NASDAQ:CRBU) Revenues

Caribou Biosciences, Inc. ( NASDAQ:CRBU ) shareholders will have a reason to smile today, with the analysts making...
Seeking Alpha • Nov 03

Caribou Biosciences: A Much Anticipated Data Readout Does Not Quite Get My Buy

Summary Caribou Biosciences has recently reported some very exciting early data, with more in their allogeneic CAR T-cell pipeline guided by the end of the year. Encouraging myeloma data point to possible best-in-class anti-BCMA cell therapy, which could serve a very viable niche. Although there is sufficient cash to reach another data readout, I am affirming a "Hold" for CRBU here based on the need for more proving of these programs. Read the full article on Seeking Alpha
Seeking Alpha • Jan 02

Caribou Biosciences: CB-010 And Other CAR-Ts Pressing Forward Despite Initial Data

Summary Caribou Biosciences, Inc. data from phase 1 ANTLER study, using CB-010 to target 2nd-line LBCLC patients and prior CD19 treated patients with partial matched HLA, expected in the 1st half of 2025. The global B-Cell Lymphoma treatment market size is expected to reach $13.14 billion by 2030. Dose-escalation data from the phase 1 CaMMouflage trial, using CB-011 for the targeting of patients with relapsed/refractory Multiple Myeloma, expected 1st half of 2025. CRBU's initiation of the phase 1 GALLOP trial, using CB-010 for the treatment of patients with lupus nephritis and extrarenal lupus, expected in the upcoming months. Read the full article on Seeking Alpha
Analyseartikel • Dec 31

Here's Why Caribou Biosciences (NASDAQ:CRBU) Must Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analyseartikel • Nov 05

Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Shares Bounce 25% But Its Business Still Trails The Industry

Caribou Biosciences, Inc. ( NASDAQ:CRBU ) shareholders would be excited to see that the share price has had a great...
Seeking Alpha • Sep 30

Caribou Biosciences: CB-010, chRDNA Technology Continue To Show Promise In Gene Editing

Summary Caribou Biosciences focuses on allogeneic CAR-T therapies for hematological cancers and autoimmune diseases, leveraging its unique chRDNA genome-editing technology. In my view, CRBU's chRDNA platform offers precise genome editing and could potentially outperform competitors like Allogene Therapeutics. CRBU's flagship candidate, CB-010, shows promising results in Phase 1 trials for large B cell lymphoma, with long-term complete response rates. The FDA's Fast Track Designation for CB-010 and CB-012 supports optimism, but definitive Phase 3 data is needed to corroborate CRBU's still speculative IP. CRBU's valuation is significantly lower than its peers, but it has sufficient resources until 2H2026. Thus, I rate it a "buy" after appreciating by over 20% since my previous article. Read the full article on Seeking Alpha
Analyseartikel • Sep 06

Here's Why We're Watching Caribou Biosciences' (NASDAQ:CRBU) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analyseartikel • Jul 26

Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Share Price Boosted 39% But Its Business Prospects Need A Lift Too

Those holding Caribou Biosciences, Inc. ( NASDAQ:CRBU ) shares would be relieved that the share price has rebounded 39...
Seeking Alpha • Jul 03

Caribou Biosciences: Promising Gene Editing Therapies With Strong Buy Potential

Summary Caribou Biosciences develops allogeneic therapies using CRISPR technology, focusing on hematologic cancers and autoimmune diseases. CB-010, CB-011, and CB-012 are in Phase 1 clinical trials, with CB-010 showing promising results for B cell non-Hodgkin lymphoma. Evercore downgraded CRBU’s stock due to high COGS concerns, but its superior efficacy and safety might justify higher prices. CRBU’s CB-010 achieved a 92% ORR and favorable safety compared to competitors Yescarta and Kymriah. Despite early-stage risks, CRBU’s undervaluation and large TAM present a compelling speculative buy opportunity. Read the full article on Seeking Alpha
Analyseartikel • Jun 05

Little Excitement Around Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Revenues As Shares Take 43% Pounding

To the annoyance of some shareholders, Caribou Biosciences, Inc. ( NASDAQ:CRBU ) shares are down a considerable 43% in...
Seeking Alpha • Apr 18

Caribou Biosciences: 2 Clinical Data Updates In 2024 Could Bring Value

Summary Caribou Biosciences, Inc. is expected to produce results from phase 1 ANTLER study, using CB-010 for the treatment of 2nd-line large B-cell lymphoma patients, at medical meeting Q2 of 2024. Initial dose escalation data from the phase 1 ANTLER study indicated that CB-010 was able to generate a 90% objective response rate for patients with relapsed or refractory LBCL. Clearance was given by the FDA to initiate a phase 1 study using CB-010 for patients with lupus nephritis and extrarenal lupus; Trial initiation expected by the end of 2024. Initial dose-escalation data from the phase 1 CaMMouflage study, using CB-011 for the treatment of patients with relapsed or refractory multiple myeloma patients by end of 2024. Read the full article on Seeking Alpha
Analyseartikel • Apr 17

More Unpleasant Surprises Could Be In Store For Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Shares After Tumbling 25%

Caribou Biosciences, Inc. ( NASDAQ:CRBU ) shareholders that were waiting for something to happen have been dealt a blow...
Analyseartikel • Feb 15

Caribou Biosciences, Inc.'s (NASDAQ:CRBU) 25% Share Price Surge Not Quite Adding Up

Despite an already strong run, Caribou Biosciences, Inc. ( NASDAQ:CRBU ) shares have been powering on, with a gain of...
Seeking Alpha • Feb 01

Caribou Biosciences: Under The Radar With Catalysts Approaching

Summary CRBU has provided regulatory and clinical updates in the past couple of months, but hasn't rallied quite like other biotech names. CRBU achieved alignment with the FDA on the comparator arm for its pivotal study of CB-010, and confirmed further data from the phase 1 ANTLER study in Q2'24. CRBU has progressed to the third dose level of CB-011 in the CaMMouflage study, and confirmed initial data are expected by year-end 2024. Read the full article on Seeking Alpha
Analyseartikel • Jan 10

Caribou Biosciences (NASDAQ:CRBU) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analyseartikel • Nov 18

Caribou Biosciences, Inc.'s (NASDAQ:CRBU) 28% Price Boost Is Out Of Tune With Revenues

Caribou Biosciences, Inc. ( NASDAQ:CRBU ) shareholders are no doubt pleased to see that the share price has bounced 28...
Analyseartikel • Feb 24

Companies Like Caribou Biosciences (NASDAQ:CRBU) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Seeking Alpha • Oct 12

Caribou Biosciences: Strong Momentum Possible If Higher Dose Shows Durability

Summary Caribou Biosciences' early data was good, but not that durable. However, this was the lowest dose cohort, and safety was manageable. If a higher dose, now ongoing, produces a durable response, this stock will likely go up. Caribou Biosciences (CRBU), founded by CRISPR pioneer Jennifer Doudna, is another CAR-T stock that has been down for months on end. Since my last coverage almost exactly a year ago, the stock is down 50%. Not a lot has happened with the company since then - which is one of the many reasons this stock is a laggard. Last year, we saw how the clinical hold on Allogene (ALLO) caused CRBU stock to falter. In October last year, the FDA placed a clinical hold on all 5 programs of Allogene following a report of a chromosomal abnormality in ALLO-501A CAR T cells in a patient treated in the ALPHA2 study. Per the company: The single case involves a patient with Stage IV transformed follicular lymphoma and c-myc rearrangement whose cancer was refractory to two prior lines of immune-chemotherapy and additional radiation therapy. The patient could not receive an autologous CD19 CAR T cell therapy due to manufacturing failure associated with inadequate expansion of autologous CAR T cells. Following infusion of ALLO-501A, the patient experienced Grade 1 CRS and Grade 2 ICANS, which required a course of high dose steroid therapy. The patient subsequently developed progressive pancytopenia and a bone marrow biopsy showed aplastic anemia and the presence of ALLO-501A CAR T cells with the chromosomal abnormality. Early translational data showed that the CAR T cells expanded, peaking on Day 28, and undergoing contraction thereafter. The patient had a partial response to ALLO-501A and subsequently underwent allogeneic stem cell transplantation. Prolonged cytopenia requiring rescue stem cell transplantation has been reported in autologous CAR T therapies. This has a direct bearing on Caribou. While it uses a different gene editing technology from Allogene - chRDNA, a type of Crispr, versus the latter’s TALEN, an older but more precise technology - there are enough similarities to warrant caution. The main concern is the TRAC (T Cell Receptor Alpha Constant) edit, which occurs under both programs, and which caused the pancytopenia in the Allogene patient. Even though the tech is different, these are the same edits. In January, the FDA lifted the clinical hold for Allogene, and the collective gene editing space heaved a sigh of relief. What they said: Investigations concluded that the chromosomal abnormality was unrelated to TALEN® gene editing or Allogene’s manufacturing process and had no clinical significance. The abnormality was not detected in any manufactured AlloCAR T product or in any other patient treated with the same ALLO-501A lot. The abnormality occurred in the patient after the cell product was administered. It involved regions of the T cell receptor and immunoglobulin genes known to undergo rearrangement as part of the T cell or B cell maturation process. I believe the FDA let it slide because there was just this one patient. Otherwise, there would have been further investigation - unrelated or not. In May, Caribou posted early data from the lowest dose cohort of lead candidate CB-010 in a phase 1 trial in penta- or more refractory NHL patients, and there was a strong drug response seen in patients, with all 5 of the 5 patients showing an overall response rate of 100%, while 80% of patients had no detectable evidence of cancer, i.e., they had a CR or complete response. The data was so good that the stock went up 30% despite some nagging safety issues - specifically, Grade 3 or 4 treatment emergent adverse events (TEAEs) developed in 5 of 6 patients.
Analyseartikel • Sep 16

Companies Like Caribou Biosciences (NASDAQ:CRBU) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Aktionärsrenditen

CRBUUS BiotechsUS Markt
7D-16.9%1.2%0.9%
1Y43.7%27.7%24.5%

Rendite im Vergleich zur Industrie: CRBU übertraf die Branche US Biotechs , die im vergangenen Jahr eine Rendite von 27.7 erzielte.

Rendite vs. Markt: CRBU übertraf den Markt US, der im vergangenen Jahr eine Rendite von 24.5 erzielte.

Preisvolatilität

Is CRBU's price volatile compared to industry and market?
CRBU volatility
CRBU Average Weekly Movement9.7%
Biotechs Industry Average Movement10.4%
Market Average Movement7.2%
10% most volatile stocks in US Market16.7%
10% least volatile stocks in US Market3.1%

Stabiler Aktienkurs: CRBU hatte in den letzten 3 Monaten im Vergleich zum US -Markt keine signifikante Preisvolatilität.

Volatilität im Zeitverlauf: CRBUDie wöchentliche Volatilität (10%) ist im vergangenen Jahr stabil geblieben.

Über das Unternehmen

GegründetMitarbeiterCEOWebsite
201197Rachel Haurwitzcariboubio.com

Caribou Biosciences, Inc. ist ein in der klinischen Phase befindliches biopharmazeutisches Unternehmen, das Genom-Editing mittels CRISPR (clustered regularly interspaced short palindromic repeats) betreibt. Es bietet eine Genom-Editing-Plattform an, die auf einer neuartigen CRISPR-Hybrid-RNA-DNA-Genom-Editing-Technologie basiert, die ein präzises Genom-Editing von allogenen Zelltherapien ermöglicht. Das Unternehmen entwickelt Vispacabtagene Regedleucel, eine allogene Anti-CD19-CAR-T-Zelltherapie, die sich in der klinischen Phase 1 zur Behandlung des rezidivierten oder refraktären B-Zell-Non-Hodgkin-Lymphoms befindet, sowie CB-011, eine allogene Anti-BCMA-CAR-T-Zelltherapie, die sich in der klinischen Phase 1 zur Behandlung des rezidivierten oder refraktären multiplen Myeloms befindet.

Caribou Biosciences, Inc.'s Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Caribou Biosciences im Vergleich zum Marktanteil des Unternehmens?
CRBU grundlegende Statistiken
MarktanteilUS$158.19m
Gewinn(TTM)-US$133.22m
Umsatz(TTM)US$11.20m
14.1x
Kurs-Umsatz-Verhältnis
-1.2x
Kurs-Gewinn-Verhältnis

Ist CRBU zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
CRBU Gewinn- und Verlustrechnung (TTM)
EinnahmenUS$11.20m
Kosten der EinnahmenUS$92.60m
Bruttogewinn-US$81.40m
Sonstige AusgabenUS$51.82m
Gewinn-US$133.22m

Zuletzt gemeldete Gewinne

Mar 31, 2026

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)-1.34
Bruttomarge-726.59%
Nettogewinnspanne-1,189.14%
Schulden/Eigenkapital-Verhältnis0%

Wie hat sich CRBU auf lange Sicht entwickelt?

Historische Performance und Vergleiche

Unternehmensanalyse und Finanzdaten Status

DatenZuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse2026/06/14 21:06
Aktienkurs zum Tagesende2026/06/12 00:00
Gewinne2026/03/31
Jährliche Einnahmen2025/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

PaketDatenZeitrahmenBeispiel US-Quelle *
Finanzdaten des Unternehmens10 Jahre
  • Gewinn- und Verlustrechnung
  • Kapitalflussrechnung
  • Bilanz
Konsensschätzungen der Analysten+3 Jahre
  • Finanzielle Vorausschau
  • Kursziele der Analysten
Marktpreise30 Jahre
  • Aktienkurse
  • Dividenden, Splits und Aktionen
Eigentümerschaft10 Jahre
  • Top-Aktionäre
  • Insiderhandel
Verwaltung10 Jahre
  • Das Führungsteam
  • Direktorium
Wichtige Entwicklungen10 Jahre
  • Ankündigungen des Unternehmens

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Caribou Biosciences, Inc. wird von 10 Analysten beobachtet. 6 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

AnalystEinrichtung
Alec StranahanBofA Global Research
Leah Rush CannBrookline Capital Markets
Yigal NochomovitzCitigroup Inc